Principles of proteomics and its applications in cancer

被引:15
作者
Chuthapisith, S. [1 ]
Layfield, R.
Kerr, I. D.
Eremin, O.
机构
[1] Univ Nottingham, Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England
[2] Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England
[3] Lincoln Cty Hosp, Dept Res & Dev, Lincoln LN2 5QY, England
来源
SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND | 2007年 / 5卷 / 01期
关键词
proteomics; cancer; SELDI-TOF-MS; BREAST-CANCER; MASS-SPECTROMETRY; OVARIAN-CANCER; SERUM BIOMARKERS; PROSTATE-CANCER; CELL-LINES; 2-DIMENSIONAL ELECTROPHORESIS; PATTERNS; IDENTIFICATION;
D O I
10.1016/S1479-666X(07)80107-7
中图分类号
R61 [外科手术学];
学科分类号
摘要
During the past decade, genomic analyses have been introduced into cancer studies with variable success. It has become recognised, however, that genomic techniques in isolation are insufficient to study the complex pathways of carcinogenesis; this has led to the application of proteomic techniques, which allow for the reliable analysis of complex mixtures of proteins. This article reviews the basic principles of proteomics, methods currently used in proteomics including two-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS), and the application of proteornics in cancer research. Currently, proteomic technology has been used in two main areas of cancer research: early diagnosis and treatment (included prediction of response to treatment and targeting novel cancer agents). The initial results from both in vitro and in vivo studies are impressive. These technologies, particularly when combined with genomic analyses, will provide valuable insights into the molecular basis of carcinogenesis and the development of more effective anti-cancer therapies.
引用
收藏
页码:14 / 22
页数:9
相关论文
共 57 条
[1]   Mass spectrometry-based proteomics [J].
Aebersold, R ;
Mann, M .
NATURE, 2003, 422 (6928) :198-207
[2]   Moving disease biology from the lab to the clinic [J].
Anderson, KC .
CANCER, 2003, 97 (03) :796-801
[3]   A comparison of selected mRNA and protein abundances in human liver [J].
Anderson, L ;
Seilhamer, J .
ELECTROPHORESIS, 1997, 18 (3-4) :533-537
[4]   Bioinformatics in proteomics [J].
Blueggel, M ;
Chamrad, D ;
Meyer, HE .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2004, 5 (01) :79-88
[5]   Biomedical informatics for proteomics [J].
Boguski, MS ;
McIntosh, MW .
NATURE, 2003, 422 (6928) :233-237
[6]   A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431 [J].
Castagna, A ;
Antonioli, P ;
Astner, H ;
Hamdan, M ;
Righetti, SC ;
Perego, P ;
Zunino, F ;
Righetti, PG .
PROTEOMICS, 2004, 4 (10) :3246-3267
[7]   Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients [J].
Chang, JC ;
Wooten, EC ;
Tsimelzon, A ;
Hilsenbeck, SG ;
Gutierrez, MC ;
Tham, YL ;
Kalidas, M ;
Elledge, R ;
Mohsin, S ;
Osborne, CK ;
Chamness, GC ;
Allred, DC ;
Lewis, MT ;
Wong, H ;
O'Connell, P .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1169-1177
[8]   Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer [J].
Chang, JC ;
Wooten, EC ;
Tsimelzon, A ;
Hilsenbeck, SG ;
Gutierrez, MC ;
Elledge, R ;
Mohsin, S ;
Osborne, CK ;
Chamness, GC ;
Allred, DC ;
O'Connell, P .
LANCET, 2003, 362 (9381) :362-369
[9]   Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population [J].
Chen, YD ;
Zheng, S ;
Yu, JK ;
Hu, X .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8380-8385
[10]  
CHUTHAPISITH S, 2006, P 19 M EUR ASS CANC, P192